Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study - PubMed (original) (raw)
doi: 10.1111/1753-0407.12237. Epub 2014 Dec 22.
Kathryn H Williams 1 2 3 4, Emilia Prakoso 1 4 5, Anne-Sophie Veillard 1 3, Nicholas A Shackel 1 4 5, Belinda Brooks 6 4, Yangmin Bu 7, Erika Cavanagh 4, Jim Raleigh 4, Susan V McLennan 1 2 4, Geoffrey W McCaughan 1 4 5, Fiona M Keane 1 5, Amany Zekry 7 8, Mark D Gorrell 1 5, Stephen M Twigg 1 2 4
Affiliations
- PMID: 25350950
- DOI: 10.1111/1753-0407.12237
Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study
Kathryn H Williams et al. J Diabetes. 2015 Nov.
Abstract
Background: Intrahepatic expression of dipeptidyl peptidase-4 (DPP4), and circulating DPP4 (cDPP4) levels and its enzymatic activity, are increased in non-alcoholic fatty liver disease (NAFLD) and in type 2 diabetes mellitus and/or obesity. DPP4 has been implicated as a causative factor in NAFLD progression but few studies have examined associations between cDPP4 activity and NAFLD severity in humans. This study aimed to examine the relationship of cDPP4 activity with measures of liver disease severity in NAFLD in subjects with diabetes and/or obesity.
Methods: cDPP4 was measured in 106 individuals with type 2 diabetes who had transient elastography (Cohort 1) and 145 individuals with morbid obesity who had liver biopsy (Cohort 2). Both cohorts had caspase-cleaved keratin-18 (ccK18) measured as a marker of apoptosis.
Results: Natural log increases in cDPP4 activity were associated with increasing quartiles of ccK18 (Cohorts 1 and 2) and with median liver stiffness ≥10.3 kPa (Cohort 1) and significant fibrosis (F ≥ 2) on liver biopsy (Cohort 2).
Conclusions: In diabetes and/or obesity, cDPP4 activity is associated with current apoptosis and liver fibrosis. Given the pathogenic mechanisms by which DPP4 may progress NAFLD, measurement of cDPP4 activity may have utility to predict disease progression and DPP4 inhibition may improve liver histology over time.
Keywords: apoptosis; diabetes; dipeptidyl peptidase-4; fibrosis; non-alcoholic fatty liver disease; 关键词：细胞凋亡，糖尿病，二肽基肽酶-4，纤维化，非酒精性脂肪性肝病.
© 2014 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and Wiley Publishing Asia Pty Ltd.
Similar articles
- Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.
Sagara M, Iijima T, Kase M, Kato K, Sakurai S, Tomaru T, Jojima T, Usui I, Aso Y. Sagara M, et al. J Diabetes Complications. 2021 May;35(5):107885. doi: 10.1016/j.jdiacomp.2021.107885. Epub 2021 Feb 6. J Diabetes Complications. 2021. PMID: 33602617 - Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity.
Williams KH, Viera de Ribeiro AJ, Prakoso E, Veillard AS, Shackel NA, Bu Y, Brooks B, Cavanagh E, Raleigh J, McLennan SV, McCaughan GW, Bachovchin WW, Keane FM, Zekry A, Twigg SM, Gorrell MD. Williams KH, et al. Diabetes Res Clin Pract. 2015 Jun;108(3):466-72. doi: 10.1016/j.diabres.2015.02.024. Epub 2015 Mar 11. Diabetes Res Clin Pract. 2015. PMID: 25836944 - An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes.
Williams KH, Burns K, Constantino M, Shackel NA, Prakoso E, Wong J, Wu T, George J, McCaughan GW, Twigg SM. Williams KH, et al. J Diabetes Complications. 2015 Nov-Dec;29(8):1240-7. doi: 10.1016/j.jdiacomp.2015.06.015. Epub 2015 Jul 3. J Diabetes Complications. 2015. PMID: 26297218 - Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.
Stål P. Stål P. World J Gastroenterol. 2015 Oct 21;21(39):11077-87. doi: 10.3748/wjg.v21.i39.11077. World J Gastroenterol. 2015. PMID: 26494963 Free PMC article. Review. - Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease.
Castera L. Castera L. Semin Liver Dis. 2015 Aug;35(3):291-303. doi: 10.1055/s-0035-1562948. Epub 2015 Sep 17. Semin Liver Dis. 2015. PMID: 26378645 Review.
Cited by
- Pharmacotherapies of NAFLD: updated opportunities based on metabolic intervention.
Shao Y, Chen S, Han L, Liu J. Shao Y, et al. Nutr Metab (Lond). 2023 Jul 6;20(1):30. doi: 10.1186/s12986-023-00748-x. Nutr Metab (Lond). 2023. PMID: 37415199 Free PMC article. Review. - Hepatocyte-derived DPP4 regulates portal GLP-1 bioactivity, modulates glucose production, and when absent influences NAFLD progression.
Trzaskalski NA, Vulesevic B, Nguyen MA, Jeraj N, Fadzeyeva E, Morrow NM, Locatelli CA, Travis N, Hanson AA, Nunes JR, O'Dwyer C, van der Veen JN, Lorenzen-Schmidt I, Seymour R, Pulente SM, Clément AC, Crawley AM, Jacobs RL, Doyle MA, Cooper CL, Kim KH, Fullerton MD, Mulvihill EE. Trzaskalski NA, et al. JCI Insight. 2023 Jan 24;8(2):e154314. doi: 10.1172/jci.insight.154314. JCI Insight. 2023. PMID: 36472923 Free PMC article. - Dipeptidyl Peptidase 4 (DPP4) as A Novel Adipokine: Role in Metabolism and Fat Homeostasis.
Barchetta I, Cimini FA, Dule S, Cavallo MG. Barchetta I, et al. Biomedicines. 2022 Sep 16;10(9):2306. doi: 10.3390/biomedicines10092306. Biomedicines. 2022. PMID: 36140405 Free PMC article. Review. - Dipeptidyl Peptidase Inhibition Enhances CD8 T Cell Recruitment and Activates Intrahepatic Inflammasome in a Murine Model of Hepatocellular Carcinoma.
Henderson JM, Xiang MSW, Huang JC, Wetzel S, Jiang L, Lai JH, Wu W, Kench JG, Bachovchin WW, Roediger B, McCaughan GW, Zhang HE, Gorrell MD. Henderson JM, et al. Cancers (Basel). 2021 Nov 1;13(21):5495. doi: 10.3390/cancers13215495. Cancers (Basel). 2021. PMID: 34771657 Free PMC article. - SARS-CoV-2 and diabetes: A potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19.
Kifle ZD, Woldeyohanin AE, Demeke CA. Kifle ZD, et al. Metabol Open. 2021 Dec;12:100134. doi: 10.1016/j.metop.2021.100134. Epub 2021 Oct 13. Metabol Open. 2021. PMID: 34661092 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous